01 Host-Response Testing Moves Sepsis Detection Beyond Pathogen Identification The sepsis diagnostics market is shifting toward host-response testing that measures how a patient’s immune system reacts to infection, rather than relying only on finding the pathogen. This approach is useful because sepsis can develop before cultures become positive and can resemble non-infectious inflammation. New tests use cell mechanics, RNA signatures, and multi-biomarker algorithms to estimate sepsis risk within emergency-department timelines. Faster risk classification can help clinicians decide which patients need closer monitoring, additional testing, or urgent treatment. As these technologies mature, competition is moving toward rapid turnaround, bedside usability, and clinically actionable risk scores that fit existing emergency-care workflows. In March 2025, The U.S. FDA issued a 510(k) substantial-equivalence decision for Cytovale’s IntelliSep Test, a deformability-cytometry system for sepsis risk assessment.
01 Growing Hospital Sepsis Programs Increase Demand for Early Diagnostic Support Hospitals are also building formal sepsis programs, standard screening protocols, and tailored order sets, creating a larger installed base for diagnostic technologies. This demand is not limited to one pathogen because bacterial, viral, and fungal infections can all contribute to sepsis. As hospitals strengthen sepsis pathways, diagnostics become a central part of time-sensitive clinical decision-making.
01 Laboratory Infrastructure Gaps Limit Advanced Testing in Resource-Constrained Regions High cost and laboratory requirements can restrain the adoption of advanced sepsis diagnostics, especially in low-resource health systems. Transport delays can further reduce the value of testing when samples must travel to centralized laboratories. These barriers are important because lower-income settings carry a large share of severe infection and neonatal sepsis burden. Hospitals with limited budgets may therefore continue relying heavily on clinical assessment and basic biomarkers. Until rapid tests become simpler, affordable, and usable closer to the patient, access will remain uneven across regions.
01 Faster Susceptibility Testing Creates Value Beyond Pathogen Detection Rapid antimicrobial susceptibility testing is creating a commercial opportunity within sepsis diagnostics by helping clinicians move from broad empiric antibiotics to more targeted treatment sooner. Traditional susceptibility testing can extend well beyond initial pathogen detection, leaving physicians uncertain about which antibiotic will work. Faster phenotypic systems can test organisms from positive blood cultures and provide actionable resistance information within the same clinical day. This supports antimicrobial stewardship, reduces unnecessary exposure to ineffective drugs, and can improve laboratory value beyond simple organism identification.
01 Sepsis Heterogeneity Makes Universal Diagnostic Validation Difficult Developing a universally reliable sepsis test remains difficult because sepsis is a highly heterogeneous syndrome rather than a single disease with one measurable marker. Patient age, immune status, infection site, pathogen type, comorbidities, and treatment timing can all change the host response. Many non-infectious conditions can also produce similar inflammation and organ dysfunction. This makes validation difficult because there is no perfect gold-standard test against which every new diagnostic can be compared. Expert reviewers may disagree about whether a patient truly had infection or sepsis, creating uncertainty in clinical studies. Developers therefore face complex trial design, regulatory, and performance-validation requirements before new tests achieve broad hospital adoption.
June 2026 bioMérieux expanded its sepsis diagnostics portfolio with enhanced capabilities for the VITEK® MS and VITEK® REVEAL™ platforms, supporting faster pathogen identification and antimicrobial resistance detection for critical care settings.
May 2026 Thermo Fisher Scientific launched expanded molecular diagnostic solutions for bloodstream infection testing, strengthening rapid sepsis detection workflows through advanced PCR-based technologies.
March 2026 Roche Diagnostics expanded its infectious disease diagnostics portfolio with new molecular testing capabilities designed to support faster identification of pathogens associated with severe infections, including sepsis-related conditions.
January 2026 Bruker expanded its MALDI Biotyper® platform with improved microbial identification workflows, enhancing rapid laboratory diagnostics for bloodstream infections and sepsis management.